Monoclonal Antibody Authorized to Protect At-Risk People From COVID-19

The US Food and Drug Administration (FDA) granted emergency use authorization to pemivibart, marketed as Pemgarda, to protect people who are immunocompromised from COVID-19. Pemivibart is the only long-acting monoclonal antibody available in the US for preexposure prophylaxis after the FDA revoked authorization of tixagevimab copackaged with cilgavimab, also known as Evusheld, in January 2023.